Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 1.40
IRWD's Cash to Debt is ranked higher than
70% of the 1152 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.37 vs. IRWD: 1.40 )
IRWD' s 10-Year Cash to Debt Range
Min: 1.1   Max: 420.39
Current: 1.4

1.1
420.39
Equity to Asset 0.27
IRWD's Equity to Asset is ranked lower than
51% of the 1034 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.58 vs. IRWD: 0.27 )
IRWD' s 10-Year Equity to Asset Range
Min: -1.86   Max: 0.63
Current: 0.27

-1.86
0.63
F-Score: 4
Z-Score: 0.62
M-Score: -1.64
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -221.58
IRWD's Operating margin (%) is ranked lower than
53% of the 1102 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.84 vs. IRWD: -221.58 )
IRWD' s 10-Year Operating margin (%) Range
Min: -1101.36   Max: -48.43
Current: -221.58

-1101.36
-48.43
Net-margin (%) -248.07
IRWD's Net-margin (%) is ranked lower than
54% of the 1102 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.10 vs. IRWD: -248.07 )
IRWD' s 10-Year Net-margin (%) Range
Min: -1192.31   Max: -48.34
Current: -248.07

-1192.31
-48.34
ROE (%) -167.60
IRWD's ROE (%) is ranked lower than
56% of the 1129 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.93 vs. IRWD: -167.60 )
IRWD' s 10-Year ROE (%) Range
Min: -299.34   Max: -48.14
Current: -167.6

-299.34
-48.14
ROA (%) -54.22
IRWD's ROA (%) is ranked lower than
54% of the 1161 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.32 vs. IRWD: -54.22 )
IRWD' s 10-Year ROA (%) Range
Min: -107.22   Max: -22.85
Current: -54.22

-107.22
-22.85
ROC (Joel Greenblatt) (%) -490.15
IRWD's ROC (Joel Greenblatt) (%) is ranked lower than
51% of the 1156 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.14 vs. IRWD: -490.15 )
IRWD' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -672.79   Max: -194.55
Current: -490.15

-672.79
-194.55
Revenue Growth (3Y)(%) -5.30
IRWD's Revenue Growth (3Y)(%) is ranked higher than
57% of the 932 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.80 vs. IRWD: -5.30 )
IRWD' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: -5.3
Current: -5.3

EBITDA Growth (3Y)(%) 27.50
IRWD's EBITDA Growth (3Y)(%) is ranked higher than
91% of the 839 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.70 vs. IRWD: 27.50 )
IRWD' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 52
Current: 27.5

0
52
EPS Growth (3Y)(%) 28.80
IRWD's EPS Growth (3Y)(%) is ranked higher than
90% of the 811 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.80 vs. IRWD: 28.80 )
IRWD' s 10-Year EPS Growth (3Y)(%) Range
Min: 0   Max: 54.3
Current: 28.8

0
54.3
» IRWD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

IRWD Guru Trades in Q1 2014

John Burbank 16,207 sh (New)
Vanguard Health Care Fund 3,901,498 sh (+15.97%)
» More
Q2 2014

IRWD Guru Trades in Q2 2014

Joel Greenblatt 27,789 sh (New)
Vanguard Health Care Fund 3,901,498 sh (unchged)
John Burbank Sold Out
» More
Q3 2014

IRWD Guru Trades in Q3 2014

Steven Cohen 1,292,500 sh (New)
Vanguard Health Care Fund 3,901,498 sh (unchged)
Joel Greenblatt Sold Out
» More
Q4 2014

IRWD Guru Trades in Q4 2014

Steven Cohen 1,500,100 sh (+16.06%)
Vanguard Health Care Fund 4,166,598 sh (+6.79%)
» More
» Details

Insider Trades

Latest Guru Trades with IRWD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 24.51
IRWD's Forward P/E is ranked higher than
81% of the 1267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. IRWD: 24.51 )
N/A
P/B 23.90
IRWD's P/B is ranked lower than
61% of the 1267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.13 vs. IRWD: 23.90 )
IRWD' s 10-Year P/B Range
Min: 5.46   Max: 46.91
Current: 23.9

5.46
46.91
P/S 27.04
IRWD's P/S is ranked lower than
69% of the 1267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.19 vs. IRWD: 27.04 )
IRWD' s 10-Year P/S Range
Min: 2.68   Max: 75.05
Current: 27.04

2.68
75.05
Current Ratio 4.79
IRWD's Current Ratio is ranked higher than
87% of the 1100 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.13 vs. IRWD: 4.79 )
IRWD' s 10-Year Current Ratio Range
Min: 2.33   Max: 5.58
Current: 4.79

2.33
5.58
Quick Ratio 4.70
IRWD's Quick Ratio is ranked higher than
89% of the 1100 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.60 vs. IRWD: 4.70 )
IRWD' s 10-Year Quick Ratio Range
Min: 2.33   Max: 5.04
Current: 4.7

2.33
5.04
Days Inventory 218.42
IRWD's Days Inventory is ranked higher than
60% of the 1267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 148.81 vs. IRWD: 218.42 )
IRWD' s 10-Year Days Inventory Range
Min: 193.31   Max: 1266.91
Current: 218.42

193.31
1266.91
Days Sales Outstanding 0.05
IRWD's Days Sales Outstanding is ranked higher than
100% of the 1267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 89.68 vs. IRWD: 0.05 )
IRWD' s 10-Year Days Sales Outstanding Range
Min: 0.05   Max: 889.76
Current: 0.05

0.05
889.76

Valuation & Return

vs
industry
vs
history
Price/Net Cash 755.50
IRWD's Price/Net Cash is ranked higher than
78% of the 1267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. IRWD: 755.50 )
IRWD' s 10-Year Price/Net Cash Range
Min: 9.67   Max: 766
Current: 755.5

9.67
766
Price/Net Current Asset Value 377.80
IRWD's Price/Net Current Asset Value is ranked higher than
69% of the 1267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. IRWD: 377.80 )
IRWD' s 10-Year Price/Net Current Asset Value Range
Min: 8.77   Max: 47.88
Current: 377.8

8.77
47.88
Price/Tangible Book 24.00
IRWD's Price/Tangible Book is ranked lower than
55% of the 1267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.30 vs. IRWD: 24.00 )
IRWD' s 10-Year Price/Tangible Book Range
Min: 6.43   Max: 36.28
Current: 24

6.43
36.28
Price/Median PS Value 1.30
IRWD's Price/Median PS Value is ranked higher than
77% of the 1267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.60 vs. IRWD: 1.30 )
IRWD' s 10-Year Price/Median PS Value Range
Min: 0.38   Max: 2.69
Current: 1.3

0.38
2.69
Earnings Yield (Greenblatt) -8.40
IRWD's Earnings Yield (Greenblatt) is ranked lower than
55% of the 1148 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.90 vs. IRWD: -8.40 )
IRWD' s 10-Year Earnings Yield (Greenblatt) Range
Min: -8.9   Max: 0
Current: -8.4

-8.9
0

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare: » details
Traded in other countries:I76.Germany,
Ironwood Pharmaceuticals Inc was incorporated in Delaware on January 5, 1998. On April 7, 2008, the Company changed its name from Microbia, Inc. to Ironwood Pharmaceuticals, Inc. The Company is an entrepreneurial pharmaceutical company that discovers, develops and intends to commercialize differentiated medicines that improve patients' lives. The Company currently operates its human therapeutics business segment. Human therapeutics segment consists of the development and commercialization of its product candidates, including linaclotide. The Company is subject to federal, state, city and local laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous materials.
» More Articles for IRWD

Headlines

Articles On GuruFocus.com
Weekly 3-Year Low Highlight: EXC, RVBD, IRWD, SHOS Oct 27 2013 
Five-Year Lows: Singapore Airlines Limited, Gold Field Ltd., Ironwood Pharmaceuticals Inc., Northwes Oct 22 2013 
Weekly CEO Buys Highlight: GDOT, VOCS, PES, IRWD, ABR Nov 11 2012 
Edward Owens Made Few Purchases In Times of Changes: Boston Scientific Corp., Ironwood Pharmaceutica May 10 2010 
Vanguard Health Care Fund Buys Ironwood Pharmaceuticals Inc., Johnson & Johnson, Boston Scientific C May 06 2010 


More From Other Websites
Ironwood Pharmaceuticals Appoints Lawrence Olanoff, M.D., Ph.D., to Board of Directors Apr 16 2015
IRONWOOD PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers,... Apr 16 2015
Ironwood Pharmaceuticals Appoints Lawrence Olanoff, M.D., Ph.D., to Board of Directors Apr 16 2015
Ironwood Pharmaceuticals to Host First Quarter 2015 Investor Update Call Apr 15 2015
Ironwood Pharmaceuticals to Host First Quarter 2015 Investor Update Call Apr 15 2015
Actavis and Rhythm Start Mid-Stage Study on Relamorelin - Analyst Blog Apr 09 2015
Here's how much Mass. commercial-stage biotechs spent on R&D last year Apr 06 2015
Sucampo Stock Spikes On Bullish Initiation Report Apr 06 2015
BioMed scores against rival Alexandria with new lease to Biogen Apr 02 2015
Exact Sciences and Ironwood Pharmaceuticals Enter Co-Promotion Agreement for Cologuard® Mar 19 2015
Theravance Biopharma's Velusetrag Enters Phase IIb Study - Analyst Blog Mar 13 2015
Ironwood, Exact Sciences Ink Cologuard Co-Promotion Deal - Analyst Blog Mar 10 2015
Exact Sciences and Ironwood Pharmaceuticals Enter Co-Promotion Agreement for Cologuard® Mar 09 2015
Exact Sciences and Ironwood Pharmaceuticals Enter Co-Promotion Agreement for Cologuard® Mar 09 2015
Ironwood Commences Dosing in Phase I Study on IW-1973 - Analyst Blog Mar 06 2015
Ironwood Pharmaceuticals Initiates Phase I Clinical Study of sGC Stimulator IW-1973 Mar 05 2015
Ironwood Pharmaceuticals to Present at Barclays Global Healthcare Conference Mar 05 2015
Ironwood Pharmaceuticals Initiates Phase I Clinical Study of Sgc Stimulator IW-1973 Mar 05 2015
Ironwood Pharmaceuticals to Present at Barclays Global Healthcare Conference Mar 04 2015
Coverage initiated on Ironwood Pharma by Barclays Mar 04 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK